Active Not RecruitingNCT06491914
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
PHASE3 · 1,126 planned enrolment
- Countries listed
- 2
- Registry update
- September 18, 2026
